{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peptide+vaccine&page=11", "query": { "intervention": "Peptide vaccine", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 749, "total_pages": 75, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peptide+vaccine&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peptide+vaccine&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T10:03:27.323Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07266558", "title": "A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "SARS-CoV-2" ], "interventions": [ { "name": "mRNA-1273", "type": "BIOLOGICAL" }, { "name": "mRNA-1283", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "50 Years to 64 Years" }, "enrollment_count": 30000, "start_date": "2025-11-26", "completion_date": "2027-06-16", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-14T10:03:27.323Z", "location_count": 150, "location_summary": "Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 127 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07266558" }, { "nct_id": "NCT01774578", "title": "Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer", "Progression of Non-small Cell Lung Cancer", "Non-small Cell Lung Cancer Recurrent" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "HyperAcute®-Lung Immunotherapy", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2013-02", "completion_date": "2016-06-18", "has_results": false, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-10-14T10:03:27.323Z", "location_count": 24, "location_summary": "Santa Rosa, California • Stamford, Connecticut • Gainesville, Florida + 20 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Arlington Heights", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01774578" }, { "nct_id": "NCT00020358", "title": "Vaccine Therapy in Treating Patients With Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" }, { "name": "tyrosinase peptide", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": null, "start_date": "2000-09", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-10-14T10:03:27.323Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020358" }, { "nct_id": "NCT04368728", "title": "Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "SARS-CoV-2 Infection", "COVID-19" ], "interventions": [ { "name": "BNT162b1", "type": "BIOLOGICAL" }, { "name": "BNT162b2", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "BNT162b2SA", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 46969, "start_date": "2020-04-29", "completion_date": "2023-02-10", "has_results": true, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-10-14T10:03:27.323Z", "location_count": 154, "location_summary": "Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 106 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04368728" }, { "nct_id": "NCT00091286", "title": "Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Craig L Slingluff, Jr", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 11, "start_date": "2003-03-24", "completion_date": "2008-02-15", "has_results": false, "last_update_posted_date": "2020-03-30", "last_synced_at": "2026-10-14T10:03:27.323Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00091286" }, { "nct_id": "NCT00612222", "title": "Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Skin Cancer" ], "interventions": [ { "name": "autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes", "type": "BIOLOGICAL" }, { "name": "ALVAC MART-1 Vaccine", "type": "BIOLOGICAL" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2008-01", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2015-10-28", "last_synced_at": "2026-10-14T10:03:27.323Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00612222" }, { "nct_id": "NCT00437502", "title": "A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Epithelial Ovarian, Tubal or Peritoneal Cancer" ], "interventions": [ { "name": "tumor peptide vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Michael Morse, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 8, "start_date": "2007-03", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2012-11-19", "last_synced_at": "2026-10-14T10:03:27.323Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00437502" }, { "nct_id": "NCT06672055", "title": "A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "SARS-CoV2", "COVID-19" ], "interventions": [ { "name": "VXA-CoV2-3.1", "type": "BIOLOGICAL" }, { "name": "COMIRNATY®", "type": "BIOLOGICAL" }, { "name": "VXA-CoV2-3.3", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vaxart", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5485, "start_date": "2024-10-08", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-14T10:03:27.323Z", "location_count": 145, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 126 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06672055" }, { "nct_id": "NCT00390338", "title": "Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "polarized dendritic cells", "type": "BIOLOGICAL" }, { "name": "non-polarized dendritic cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pawel Kalinski", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2006-10", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2017-09-26", "last_synced_at": "2026-10-14T10:03:27.323Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00390338" }, { "nct_id": "NCT04449926", "title": "BCG and Plasma Amyloid in Non-Demented Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer Disease, Late Onset" ], "interventions": [ { "name": "Bacillus of Calmette and Guerin (BCG)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Mindful Diagnostics and Therapeutics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "50 Years to 80 Years" }, "enrollment_count": 49, "start_date": "2020-11-09", "completion_date": "2021-12-05", "has_results": false, "last_update_posted_date": "2021-12-23", "last_synced_at": "2026-10-14T10:03:27.323Z", "location_count": 1, "location_summary": "Eau Claire, Wisconsin", "locations": [ { "city": "Eau Claire", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04449926" } ] }